Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Aurobindo Pharma Ltd
483
•Aurobindo Pharma Ltd•April 18, 2017

Aurobindo Pharma Ltd – FDA 483, Apr 18, 2017

Record Details

This FDA Form 483 document outlines several significant observations regarding laboratory controls and the quality control unit at an unnamed facility.

**Violations and Observations:**

* **Laboratory Controls Deficiencies:** The facility's laboratory controls do not incorporate scientifically sound and appropriate sampling plans and test procedures. These procedures are crucial for ensuring that components and drug products consistently meet established standards for identity, strength, quality, and purity. * **Quality Control Unit Authority:** The quality control unit lacks the necessary authority to thoroughly investigate errors that have occurred during operations. This limitation compromises their ability to identify root causes and implement effective corrective actions. * **Unwritten/Unfollowed Procedures:** The responsibilities and procedures governing the quality control unit are not documented in writing or are not fully adhered to as required. This absence of formal, followed procedures can lead to inconsistencies and a lack of accountability. * **Undocumented Deviations:** Deviations from written test procedures are not being recorded and justified. This omission prevents proper tracking, evaluation, and resolution of non-conforming events. * **Unassessed Test Method Sensitivity:** The sensitivity of test methods has not been adequately assessed. Without this assessment, there is no assurance that the methods are capable of detecting impurities or variations at appropriate levels. * **Incomplete Laboratory Records:** Laboratory records do not contain complete data derived from all tests, examinations, and assays. Comprehensive data is essential for demonstrating compliance with established specifications and standards

Company
Aurobindo Pharma Ltd
Inspection date
April 18, 2017
Office
Generic Drug User Fee Amendments
People
  • Angela Glenn
  • Cheryl A. Clausen
View Company Profile

ID · 96bc5d60-2e90-4ff4-a4e9-85bdabf692db

Violation Codes3
FD&C Act 801(a)(3)21 CFR 331(c)21 CFR 324(a)(4)

Full citation text and observation details available on the Dashboard.

Other documents for Aurobindo Pharma Ltd
  • 483 - 2023-07-21July 21, 2023
  • 483 - 2019-05-24May 24, 2019
  • 483 - 2018-12-14December 14, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Aurobindo Pharma Ltd
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.